ISAL 2019 | CPX-351 for secondary AML: pharmacokinetics, administration & impact on treatment

Jeffrey Lancet

Jeffrey Lancet, MD, of the Moffitt Cancer Center, Tampa, FL, talks to us all about CPX-351, a recent innovation in conventional chemotherapy. CPX-351 is a liposomal formulation of the optimal ratio of cytarabine and daunorubicin, which was FDA approved in August 2017 for the frontline treatment of secondary acute myeloid leukemia (AML) and EMA approved in September 2018. Dr Lancet discusses the novel nature of this delivery system and its administration, and how this affects pharmacokinetics and treatment. This interview was recorded at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

Share this video